青岛蔚蓝生物股份有限公司董事会审计委员会 对会计师事务所 2024 年度履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》《上海证券交易所上市公 司自律监管指引第 1 号—规范运作》和青岛蔚蓝生物股份有限公司（以下简称"公 司"）的《公司章程》《审计委员会工作细则》等规定和要求，董事会审计委员会 本着勤勉尽责的原则，恪尽职守，认真履职。现将董事会审计委员会对致同会计 师事务所（特殊普通合伙）（以下简称"致同所"）2024 年度履行监督职责的情 况汇报如下： 一、2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 名称：致同会计师事务所（特殊普通合伙） 统一社会信用代码：91110105592343655N 类型：特殊普通合伙企业 主要经营场所：北京市朝阳区建国门外大街 22 号赛特广场五层 首席合伙人：李惠琦 成立日期：2011 年 12 月 22 日 经营范围：审计企业会计报表，出具审计报告；验证企业资本，出具验资报 告；办理企业合并、分立、清算事宜中的审计业务，出具有关报告；基本建设年 度财务决算审 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-019 青岛蔚蓝生物股份有限公司 关于召开2024年年度股东会的通知 重要内容提示： 一、 召开会议的基本情况 (一) 股东会类型和届次 2024年年度股东会 召开的日期时间：2025 年 5 月 16 日 14 点 30 分 召开地点：青岛市崂山区九水东路 596-1 号 蔚蓝生物创新园 B 座 多媒体会 议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 股东会召开日期：2025年5月16日 本次股东会采用的网络投票系统：上海证券交易所股东大会网络投票系 统 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 (四) 现场会议召开的日期、时间和地点 网络投票起止时间：自2025 年 5 月 16 日 1、各议案已披露的时间和披露媒体 至2025 年 5 月 16 日 采用上海证券交易所网络投票系统，通过交易 ...

一、主要会计数据和财务指标 10派1元(含税) 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 17160.58万股，累计占流通股比： 67.81%，较上期变化： 64.85万股。 | 名称 持有数量(万股) | | 占总股本比例 (%) | 增减情况(万 股) | | --- | --- | --- | --- | | 青岛康地恩实业有限公司 | 11240.74 | 44.42 | 不变 | | 西藏思壮投资咨询有限公司 | 1777.55 | 7.03 | 不变 | | 西藏善诚投资咨询有限公司 | 1777.55 | 7.03 | 不变 | | 贾德强 | 947.16 | 3.74 | 不变 | | 陈刚 | 718.96 | 2.84 | 不变 | | 吴金远 | 329.54 | 1.30 | 9.15 | | 国泰中证畜牧养殖ETF | 139.32 | 0.55 | 新进 | | 魏中强 | 84.43 | 0.33 | 新进 | | MORGAN STANLEY & CO. INTERNATIONAL PLC. | 76.63 | 0.30 | 新进 | | 高盛公司有限责任 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-009 青岛蔚蓝生物股份有限公司 关于公司第五届监事会第十次会议决议的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 青岛蔚蓝生物股份有限公司（以下简称"公司"）第五届监事会第十次会议 于 2025 年 4 月 25 日在公司会议室以现场表决的方式召开，会议通知已于 2025 年 4 月 15 日以邮件形式发出。本次会议应出席监事 3 人，实际出席 3 人。会议 由公司监事会主席原妤女士主持。会议召集召开程序及审议事项符合《中华人民 共和国公司法》和《青岛蔚蓝生物股份有限公司章程》等有关规定，所形成的决 议合法有效。 二、监事会会议审议情况 1、审议并通过《关于<2024 年度监事会工作报告>的议案》 该议案尚需提交公司股东会审议。 表决票：3 票，赞成票：3 票，反对票：0 票，弃权票：0 票。 2、审议并通过《关于续聘公司 2025 年度审计机构的议案》 具体内容详见公司在上海证券交易所网站（www.sse.com.cn）披露的《 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-008 青岛蔚蓝生物股份有限公司 关于公司第五届董事会第十六次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 青岛蔚蓝生物股份有限公司（以下简称"公司"）第五届董事会第十六次会 议于 2025 年 4 月 25 日在公司会议室以现场与通讯相结合的方式召开，会议通知 已于 2025 年 4 月 15 日以邮件形式发出。本次会议应出席董事 5 人，实际出席 5 人。会议由公司董事长陈刚先生主持。会议召集召开程序及审议事项符合《中华 人民共和国公司法》和《青岛蔚蓝生物股份有限公司章程》等有关规定，所形成 的决议合法有效。 二、董事会会议审议情况 1、审议并通过《关于<2024 年度董事会工作报告>的议案》 具体内容详见公司在上海证券交易所网站（www.sse.com.cn）披露的《青岛 蔚蓝生物股份有限公司 2024 年度董事会工作报告》。 该议案尚需提交公司股东会审议。 2、审议并通过《关于<2024 年度总经理工作报告>的议案 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-010 青岛蔚蓝生物股份有限公司 2024 年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、2024 年度利润分配方案的主要内容 （一）利润分配方案的具体内容 经致同会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日，公 司期末可供分配利润为人民币 740,811,881.65 元。经董事会决议，公司 2024 年年度拟以实施权益分派股权登记日登记的总股本为基数进行利润分配。本次利 润分配方案如下： 公司拟向全体股东每 10 股派发现金红利 1.00 元（含税）。截至 2024 年 12 月 31 日，公司总股本为 253,028,866 股，以此为基数进行测算，合计拟派发现 金红利 25,302,886.60 元（含税），占 2024 年度公司合并报表中归属于上市公司 股东净利润的 40.40%，剩余未分配利润结转至下一年度。 如在本公告披露之日起至实施权益分派股权登记日期间，因可转债转股、回 购 ...

Financial Performance - The company's operating revenue for 2024 reached ¥1,320,761,061.74, representing a 10.16% increase compared to ¥1,198,902,103.15 in 2023[25] - The net profit attributable to shareholders for 2024 was ¥62,637,482.98, a decrease of 22.39% from ¥80,706,911.48 in 2023[25] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥25,154,344.46, down 40.36% from ¥42,178,764.38 in 2023[25] - The net cash flow from operating activities increased by 27.22% to ¥195,407,571.77 in 2024, compared to ¥153,592,321.71 in 2023[25] - The total assets at the end of 2024 were ¥2,981,000,556.19, a decrease of 1.75% from ¥3,034,057,625.33 at the end of 2023[25] - The net assets attributable to shareholders increased by 1.72% to ¥1,737,720,580.05 at the end of 2024, compared to ¥1,708,293,232.64 at the end of 2023[25] - The basic earnings per share for 2024 were ¥0.25, down 21.88% from ¥0.32 in 2023[26] - The diluted earnings per share for 2024 were also ¥0.25, reflecting a 21.88% decrease from ¥0.32 in 2023[26] - The weighted average return on net assets for 2024 was 3.64%, a decrease of 1.18 percentage points from 4.82% in 2023[26] Revenue Breakdown - The enzyme preparation business generated revenue of CNY 50,474.96 million, with a year-on-year increase of CNY 6,330.11 million, representing a growth rate of 14.34%[32] - The company's main business income reached CNY 1,281,793,748.24, an increase of 8.86% year-on-year, while the main business cost rose by 11.53% to CNY 712,125,052.30[69] - The revenue from overseas markets was 99,948,895.67, showing a significant increase of 19.98% year-over-year[71] - Domestic sales accounted for 1,181,844,852.57, representing an 8.02% increase from the previous year[71] Research and Development - Research and development expenses amounted to CNY 11,822.23 million, accounting for 8.95% of operating revenue, with a year-on-year growth of 6.81%[32] - The company invested CNY 118.22 million in R&D, accounting for 8.95% of its revenue, which is considered high in the industry[58] - The company has established six technology centers and two key laboratories, employing 266 dedicated R&D personnel[56] - The company has developed a high-throughput screening technology platform for microbial strains, enhancing its ability to innovate and apply new products across various sectors[45] - The company is actively developing new animal vaccines and antibiotic enhancement platforms to improve clinical outcomes and reduce antibiotic resistance[61] Market Trends and Opportunities - The enzyme and micro-ecological agent industry is in a growth phase, benefiting from increasing national emphasis on safety and environmental protection[38] - The demand for enzyme preparations is expected to continue growing due to increasing environmental protection standards and policies promoting carbon neutrality[39] - The global probiotics market is rapidly growing, with applications expanding beyond gut health to include weight management and skin health, indicating a shift towards high-value product development in the food industry[41] - The agricultural sector faces significant challenges due to soil degradation and pesticide residues, creating opportunities for microbial preparations and bio-fertilizers to improve soil health and sustainability[41] Corporate Governance and Management - The total remuneration for the board members and senior management during the reporting period amounts to CNY 568.83 million[154] - The company has maintained strict confidentiality obligations during the preparation of regular reports and significant matters, with no leakage incidents reported[153] - The total number of shares held by all board members and senior management remains unchanged at 17,409,720 shares[154] - The company held six board meetings during the year, with all directors attending[160] Environmental Initiatives - The company invested 1,178,300 RMB in environmental protection during the reporting period[189] - The company’s enzyme products are estimated to have reduced carbon dioxide emissions by approximately 2.5919 million tons in downstream applications[191] - The application of microbial agents in agriculture can fundamentally reduce the use of chemical fertilizers and pesticides, thus minimizing soil and water pollution[194] Future Outlook - The company aims to leverage its R&D capabilities to ensure steady growth in performance through innovative product offerings and market expansion strategies[103] - The company is committed to building a fair organizational environment and enhancing employee satisfaction through various development programs and cultural activities[197] - The company plans to enhance its traditional Chinese medicine production processes and expand into upstream raw material businesses to reduce costs and improve quality[143]

Financial Performance - The company's revenue for Q1 2025 was CNY 310,197,929.93, representing an increase of 8.16% compared to CNY 286,784,227.66 in the same period last year[3] - Net profit attributable to shareholders decreased by 24.73% to CNY 9,576,827.68 from CNY 12,722,943.82 year-on-year[3] - The net profit excluding non-recurring gains and losses increased by 45.44% to CNY 5,259,509.61, driven mainly by government subsidies and reduced financial income[6] - Total operating revenue for Q1 2025 reached ¥310,197,929.93, an increase of 8.8% compared to ¥286,784,227.66 in Q1 2024[16] - Net profit for Q1 2025 was ¥16,586,362.18, a decrease of 3.4% from ¥17,162,518.08 in Q1 2024[16] - The basic earnings per share decreased by 20.00% to CNY 0.04 from CNY 0.05 in the same period last year[3] - Earnings per share for Q1 2025 were ¥0.04, down from ¥0.05 in Q1 2024[17] Cash Flow - The net cash flow from operating activities improved significantly, reaching CNY 7,617,106.76, a 156.39% increase from a negative cash flow of CNY 13,507,477.33 in the previous year[3] - The net cash flow from operating activities for Q1 2025 was ¥7,617,106.76, compared to a negative ¥13,507,477.33 in Q1 2024, indicating a significant improvement[19] - Cash inflow from operating activities totaled ¥384,525,708.67 in Q1 2025, up from ¥317,112,598.93 in Q1 2024, representing an increase of approximately 21.2%[19] - The total cash outflow from operating activities increased to ¥376,908,601.91 in Q1 2025 from ¥330,620,076.26 in Q1 2024, reflecting a rise of about 14%[19] - The net cash flow from financing activities improved to ¥66,632,426.50 in Q1 2025, compared to ¥39,280,028.59 in Q1 2024, showing an increase of about 69.9%[20] Assets and Liabilities - Total assets at the end of Q1 2025 were CNY 3,025,202,671.63, up 1.48% from CNY 2,981,000,556.19 at the end of the previous year[4] - Total liabilities increased to ¥1,147,176,454.05 from ¥1,110,984,258.58, marking a rise of 3.2%[13] - The company reported a total asset of ¥3,025,202,671.63 as of the end of the reporting period, compared to ¥2,981,000,556.19 previously[14] Shareholder Information - The company reported a total of 19,490 common shareholders at the end of the reporting period[8] - The largest shareholder, Qingdao Kangdian Industrial Co., Ltd., holds 44.4% of the shares, totaling 112,407,400 shares[9] - Shareholders' equity attributable to shareholders increased slightly by 0.55% to CNY 1,747,247,606.63 from CNY 1,737,720,580.05[4] - The total equity attributable to shareholders rose to ¥1,747,247,606.63 from ¥1,737,720,580.05, showing a slight increase of 0.3%[13] Operational Costs and Expenses - Total operating costs for Q1 2025 were ¥293,945,014.79, up from ¥273,764,144.88 in Q1 2024, reflecting a rise of 7.4%[16] - Research and development expenses for Q1 2025 were ¥28,494,054.14, compared to ¥26,717,261.31 in Q1 2024, indicating a growth of 6.6%[16] - The company's cash flow statement for Q1 2025 indicates a focus on maintaining liquidity amid rising operational costs[18] Investment Activities - Cash flow from investment activities showed a net outflow of ¥82,838,281.86 in Q1 2025, compared to a net outflow of ¥64,984,676.57 in Q1 2024, indicating a worsening investment cash flow situation[20] - The cash inflow from investment activities in Q1 2025 was ¥242,602,714.00, a substantial increase from ¥17,749,411.51 in Q1 2024[20] - The cash outflow from investment activities rose significantly to ¥325,440,995.86 in Q1 2025 from ¥82,734,088.08 in Q1 2024, marking an increase of approximately 293%[20] Overall Trends - The company’s cash flow from operating activities has shown a positive trend, while investment activities have resulted in increased cash outflows, necessitating strategic adjustments[19][20]

青岛蔚蓝生物股份有限公司关于收购 青岛润博特生物科技有限公司 2024 年 度业绩承诺实现情况的说明 审核报告 致同会计师事务所（特殊普通合伙） 目 录 经审核，我们认为，蔚蓝生物公司管理层编制的业绩承诺实现情况说明 已按照《上海证券交易所上市公司自律监管指引第 1号——规范运作》的规定 编制，在所有重大方面公允反映了青岛润博特生物科技有限公司实际盈利数 与股东对公司业绩承诺的差异情况。 按照《上海证券交易所上市公司自律监管指引第 1号——规范运作》的有 关规定，编制业绩承诺实现情况说明，保证其内容真实、准确、完整，不存 在虚假记录、误导性陈述或重大遗漏是蔚蓝生物公司管理层的责任，我们的 责任是在实施审核工作的基础上对蔚蓝生物公司管理层编制的业绩承诺实现 情况说明提出鉴证结论。 我们按照《中国注册会计师其他鉴证业务准则第 3101 号—历史财务信息 审计或审阅以外的鉴证业务》的规定计划和实施审核工作，以合理确信业绩 承诺实现情况说明不存在重大错报。在审核工作中，我们结合青岛润博特生 物科技有限公司实际情况，实施了包括核查会计记录等我们认为必要的审核 程序。我们相信，我们的审核工作为提出鉴证结论提供了合理的基础 ...

青岛蔚蓝生物股份有限公司 二〇二四年度 内部控制审计报告 致同会计师事务所（特殊普通合伙） 致同会计师事务所（特殊普通合伙） 中国北京 朝阳区建国门外大街 22 号 赛特广场 5 层 邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 内部控制审计报告 致同审字（2025）第 371A017996 号 青岛蔚蓝生物股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求， 我们审计了青岛蔚蓝生物股份有限公司（以下简称蔚蓝生物公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业 内部控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效 性是蔚蓝生物公司董事会的责任。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外， 由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的 程度降低，根据内部控制审计结果推测未来内部控制的有效性具有一 ...